Aptose Biosciences, Inc. (APTO)

NASDAQ: APTO · IEX Real-Time Price · USD
0.595
+0.001 (0.17%)
At close: Sep 30, 2022 4:00 PM
0.570
-0.025 (-4.20%)
After-hours: Sep 30, 2022 5:09 PM EDT
0.17%
Market Cap 55.34M
Revenue (ttm) n/a
Net Income (ttm) -57.70M
Shares Out 93.01M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 148,555
Open 0.570
Previous Close 0.594
Day's Range 0.570 - 0.598
52-Week Range 0.540 - 2.780
Beta 1.39
Analysts Buy
Price Target 4.64 (+679.8%)
Earnings Date Nov 9, 2022

About APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops ... [Read more...]

Industry Biotechnology
Founded 1986
CEO William Rice
Employees 41
Stock Exchange NASDAQ
Ticker Symbol APTO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for APTO stock is "Buy." The 12-month stock price forecast is 4.64, which is an increase of 679.83% from the latest price.

Price Target
$4.64
(679.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference

SAN DIEGO and TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly diff...

2 weeks ago - GlobeNewsWire

Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D.

New director brings big pharma oncology experience and biotech leadership New director brings big pharma oncology experience and biotech leadership

2 weeks ago - GlobeNewsWire

Aptose's New “G3” Formulation of Luxeptinib Boosts Bioavailability

– Initial modeling predicts up to 18-fold improvement in plasma steady-state exposure –

2 weeks ago - GlobeNewsWire

Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO and TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly diffe...

1 month ago - GlobeNewsWire

Aptose Reports Results for the Second Quarter 2022

─ HM43239 Preliminary Response Rate of 43% Among R/R AML Patients with FLT3 Mutations Who Failed Prior Therapy with FLT3 inhibitors ─

2 months ago - GlobeNewsWire

Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference

SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly diffe...

2 months ago - GlobeNewsWire

Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022

SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibi...

2 months ago - GlobeNewsWire

Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

SAN DIEGO and TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly diffe...

3 months ago - GlobeNewsWire

CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3

4 months ago - GlobeNewsWire

Aptose Presents Highlights from Corporate Update and KOL Event

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3

4 months ago - GlobeNewsWire

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

SAN DIEGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differ...

4 months ago - GlobeNewsWire

Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

Clinical Updates for HM43239 and Luxeptinib

4 months ago - GlobeNewsWire

Aptose Reports Results for the First Quarter 2022

Expands HM43239 dose cohort at 160 mg

4 months ago - GlobeNewsWire

Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation

SAN DIEGO and TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differ...

4 months ago - GlobeNewsWire

Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference

SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differ...

4 months ago - GlobeNewsWire

Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation

Three Recent Peer-reviewed Journal Articles Reflect Distinctive Properties of Luxeptinib Three Recent Peer-reviewed Journal Articles Reflect Distinctive Properties of Luxeptinib

5 months ago - GlobeNewsWire

Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022

SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhib...

5 months ago - GlobeNewsWire

Aptose Announces Executive Management Changes

─ Appoints Philippe Ledru as Chief Commercial Officer ─

5 months ago - GlobeNewsWire

Aptose to Present at Canaccord Genuity's 2022 Horizons in Oncology Virtual Conference

SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly diff...

6 months ago - GlobeNewsWire

Aptose Reports Results for the Fourth Quarter and Full Year 2021

- HM43239 clinical remission at 120mg expands list of potential treatable AML populations -

6 months ago - GlobeNewsWire

Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022

SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhib...

6 months ago - GlobeNewsWire

Aptose to Present at Oppenheimer's 32nd Annual Healthcare Conference

SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underly...

7 months ago - GlobeNewsWire

5 Beaten-Down Biotech Bets to Bounce Back in 2022

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Other symbols: CELUCNSPCYADSPRB
9 months ago - Zacks Investment Research

Aptose to Participate in Two Biotech Events in January 2022

— H.C. Wainwright BIOCONNECT Virtual Conference —

9 months ago - GlobeNewsWire

Aptose Shares Fall After Ceasing APTO-253 Program

Aptose Biosciences Inc (NASDAQ: APTO) will discontinue further clinical development of APTO-253 in hematologic malignancies and solid tumors.  The decision follows the prioritization of the Company's ot...

9 months ago - Benzinga